Improved Myocardial Perfusion Assessment using High-Performance Low-Field MRI

使用高性能低场 MRI 改进心肌灌注评估

• 批准号: 10453361
• 负责人: Krishna S Nayak
• 金额: $ 24.75万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-01 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10453361
• 关键词: 3-Dimensional; Algorithms; Assessment tool; Back; Blood flow; Cardiac; Cardiac health; Catheterization; Cause of Death; Cicatrix; Clinical Protocols; Computer software; Coronary; Coronary Arteriosclerosis; Data; Diagnosis; Discipline of Nuclear Medicine; Electrocardiogram; Generations; Germany; Heart; Image; Imaging Device; Imaging Techniques; Institution; Ionizing radiation; Magnetic Resonance Imaging; Maps; Measurement; Measures; Methods; Modeling; Morphologic artifacts; Motion; Myocardial; Myocardial Infarction; Myocardial Ischemia; Myocardial perfusion; Myocardium; Operating System; Patient risk; Patients; Pattern; Performance; Perfusion; Perfusion Weighted MRI; Phase; Preparation; Property; Radiation; Recovery; Resolution; Rest; Sampling; Scanning; Signal Transduction; Slice; Source; Stress Tests; Symptoms; System; Techniques; Testing; Time; United States; base; cardiac implant; cohort; compliance behavior; coronary perfusion; cost; digital; evaluation/testing; flexibility; healthy volunteer; heart imaging; hypoperfusion; image reconstruction; imaging modality; imaging platform; implantable device; improved; in vivo; individual patient; innovation; magnetic field; novel; perfusion imaging; prognostication; real-time images; simulation; temporal measurement; tool; volunteer

PROJECT SUMMARY This project will develop and evaluate an improved tool for myocardial perfusion assessment, that will be simple, robust, and provide improved ability to resolve myocardial layers. We will achieve this by leveraging a novel high-performance low-field (HPLF) magnetic resonance imaging (MRI) platform. Rationale: Coronary artery disease (CAD) is the leading cause of death in the United States. Myocardial perfusion imaging is an essential tool in patient management, and prognostication. Myocardial first-pass perfusion (FPP) MRI is the leading non- invasive and radiation-free technique; however, it suffers from imaging artifact, limited coverage, and limited ability to resolve myocardial layers. Resolving these issues will improve our ability to detect, manage, and understand CAD. Innovation: We expect MRI FPP to greatly benefit from the HPLF MRI platform, because it promises substantially reduced artifacts, and opportunities for improved spatial coverage, spatial resolution, and temporal resolution. This project will leverage an HPLF system operating at 0.55 Tesla, to achieve improved myocardial perfusion assessments, compared to what is possible today on 1.5 Tesla and 3 Tesla systems. We will also apply novel real-time imaging techniques to avoid the need for an electrocardiogram (ECG) signal. Approach: We will develop 0.55T whole-heart MRI FPP using two contrast generation sequences in combination with stack-of-spiral (SOS) acquisition—one that uses ECG-gating and saturation recovery preparation, and one ungated approach that retrospectively identifies stable phases. The SOS sampling pattern will be optimized for CNR, boundary sharpness, and precision of myocardial perfusion measurements. Achieved spatial coverage, spatial resolution, temporal resolution, and SNR/CNR will be measured using phantoms, 10 volunteer scans, and 10 patient scans. The optimized HPLF methods will then be tested in a cohort of patients (N=20) with known non-transmural scar, and compared with standard 3T multi-slice MRI FPP, to technically validate the ability to detect non-transmural patterns of hypoperfusion, and to evaluate relative artifact levels. Broader Impact: This project will provide 0.55T MRI FPP with reduced artifact and improved spatial information, compared to what is possible at conventional MRI field strengths. In the long term, this approach could improve the diagnosis and assessment of CAD. The imaging methods developed in this project will broadly benefit cardiac and dynamic imaging on HPLF MRI platforms.

项目概要 该项目将开发和评估一种改进的心肌灌注评估工具，该工具非常简单， 强大的，并提供改进的解决心肌层的能力，我们将通过利用一种新颖的方法来实现这一目标。 高性能低场 (HPLF) 磁共振成像 (MRI) 平台。 心脏病 (CAD) 是美国的首要死因，心肌灌注成像至关重要。 心肌首过灌注 (FPP) MRI 是领先的非诊断工具。 侵入式、无辐射技术；然而，它存在成像伪影、覆盖范围有限和局限性等问题。 解决心肌层的能力将提高我们检测、管理和治疗的能力。 CAD 创新：我们期望 MRI FPP 能够充分了解 HPLF MRI 平台的优势，因为它 有望大幅减少伪影，并有机会改善空间覆盖范围、空间分辨率和 该项目将利用以 0.55 特斯拉运行的 HPLF 系统来提高时间分辨率。 心肌灌注评估，与目前 1.5 特斯拉和 3 特斯拉系统的可能性进行比较。 还将应用新颖的实时成像技术，以避免需要心电图（ECG）信号。 方法：我们将结合使用两个对比生成序列来开发 0.55T 全心 MRI FPP 螺旋堆栈 (SOS) 采集——一种使用心电图门控和饱和度恢复准备，另一种 回顾性识别稳定阶段的非门控方法将针对 SOS 采样模式进行优化。 心肌灌注空间测量的 CNR、边界锐度和精度实现了覆盖， 空间分辨率、时间分辨率和 SNR/CNR 将使用体模、10 次志愿者扫描、 然后，将在一组已知患者 (N=20) 中测试优化的 HPLF 方法。 非透壁疤痕，并与标准 3T 多层 MRI FPP 进行比较，从技术上验证其能力 检测低灌注的非透壁模式，并评估相对伪影水平：这。 与现有产品相比，该项目将提供 0.55T MRI FPP，减少伪影并改善空间信息 从长远来看，这种方法可以改善诊断和诊断。 该项目开发的成像方法将广泛有益于心脏和动力。 HPLF MRI 平台上的成像。